ERBB2 and breast carcinoma: The reasons for the observed benefit in centrally assessed HER2-negative breast cancer may be due to a wide range of FISH and IHC methodologic variables including: differing methods of semiquantitation, differing cutoffs for positivity, discordance between pathologist interpretation and/or intratumoral heterogeneity.